A Phase 3 interventional study of methotrexate and tocilizumab [RoActemra/Actemra] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 3 sites in Bosnia and Herzegovina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-07.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 82nd largest by enrollment, is one of 7 that started in 2011, is one of 47 in phase 3, and was the 53rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 92nd largest by enrollment of the 141 interventional ones that give a count, is one of 25 that started in 2011, is one of 85 in phase 3, and was the 91st registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, single arm study will assess the safety and efficacy of RoActem ra/Actemra (tocilizumab) in combination with methotrexate in patients with activ e moderate to severe rheumatoid arthritis who have an inadequate response to dis ease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Act emra at a dose of 8 mg/kg (maximum 800 mg) intravenously every 4 weeks for a tot al of 6 infusions. Methotrexate will be continued at a stable dose. Anticipated time on study treatment is 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]
stable dose as prescribed
Drug page: Tocilizumab
8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)
AEs, SAEs and AESI were recorded from the Screening Visit until the final visit at Week 24.
Time frame: Screening Visit, Baseline, Weeks 4, 8, 12, 16, 20 and 24
Mean Disease Activity Score Based on 28 Joint Count (DAS28) by Visit
DAS28 was calculated using the 28 joints count, the C-reactive protein levels (CRP) and participant's global assessment (PtGA) of disease activity. The following formula was used to determine DAS28. DAS28 (equals) = 0.56 × (square root of) √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100- millimeter \[mm\] visual analog scale \[ VAS\]). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
Time frame: Baseline, Weeks 8, 16 and 24
Percentage of Participants Achieving Low Disease Activity (LDA) and Clinical Remission (CR) as Assessed Using DAS28
DAS28 was calculated using the 28 joints count, the CRP and PtGA of disease activity. The following formula was used to determine DAS28. DAS28 = 0.56 × √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100-mm VAS). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Participants were considered to have low disease activity when DAS28 was less than or equal to (≤) 3.2 and in clinical remission when DAS28 scores were less than (\<) 2.6
Time frame: Weeks 8, 16 and 24
Swollen and Tender Joint Counts
66 and 68 joints were assessed by the physician for tenderness or swelling respectively. The joints were counted as tender/not tender (tender=1; not tender=0) and swollen/not swollen (swollen=1; not swollen=0) and scored. The scores ranged from 0 to 66 for TJC and 0 to 68 for SJC. A negative change from baseline represents an improvement.
Time frame: Baseline, Weeks 8, 16 and 24
Physician's Global Assessment of Disease Activity
Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.
Time frame: Baseline, Weeks 8, 16 and 24
Participant's Global Assessment of Disease Activity
Participant's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.
Time frame: Baseline, Weeks 8, 16 and 24
Participant's Global Assessment of Pain
Participant's global assessment of pain was performed using a 100 mm VAS ranging from no pain (0) at the left edge to unbearable pain (100) at the right edge. The distance in mm from the left edge of the scale was measured. A negative change from baseline represents an improvement.
Time frame: Baseline, Weeks 8, 16 and 24
CRP Levels
CRP is a marker of acute phase inflammation and is measured in mg/L. A negative change from baseline represents an improvement.
Time frame: Baseline, Weeks 8, 16 and 24
Erythrocyte Sedimentation Rate (ESR)
ESR is a marker of inflammation and is measured in millimeters per hour (mm/hour). A negative change from baseline represents an improvement.
Time frame: Baseline, Weeks 8, 16 and 24
| Milestone | Tocilizumab Plus Methotrexate (MTX) |
|---|---|
| Started | 71 |
| Completed | 69 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
DAS28 was calculated using the 28 joints count, the C-reactive protein levels (CRP) and participant's global assessment (PtGA) of disease activity. The following formula was used to determine DAS28. DAS28 (equals) = 0.56 × (square root of) √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100- millimeter \[mm\] visual analog scale \[ VAS\]). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity.
| units on a scale | Tocilizumab Plus MTX |
|---|---|
| Baseline (n=71) | 6.28 ± 1.06 |
| Week 8 (n=71) | 3.84 ± 1.29 |
| Change from Baseline to Week 8 (n=71) | -2.44 ± 0.98 |
| Week 16 (n=71) | 3.19 ± 1.23 |
| Change from Baseline to Week 16 (n=71) | -3.09 ± 1.01 |
| Week 24 (n=69) | 2.65 ± 1.23 |
| Change from Baseline to Week 24 (n=69) | -3.62 ± 1.22 |
DAS28 was calculated using the 28 joints count, the CRP and PtGA of disease activity. The following formula was used to determine DAS28. DAS28 = 0.56 × √(TJC28) + 0.28 × √(SJC28) + 0.36 × ln(CRP+1) + 0.014 × GH + 0.96 where, TJC28 = tender joint count on 28 joints, SJC28 = swollen joint count on 28 joints, ln = natural log, CRP = C-reactive protein (mg/L), and GH = general health, determined by participant's global assessment of disease activity (100-mm VAS). The DAS28 scale ranges from 0 to 10, where higher scores represent higher disease activity. Participants were considered to have low disease activity when DAS28 was less than or equal to (≤) 3.2 and in clinical remission when DAS28 scores were less than (\<) 2.6
| percentage of participants | Tocilizumab Plus MTX |
|---|---|
| Week 8 CR (n=71) | 14.1 |
| Week 8 LDA (n=71) | 31.0 |
| Week 16 CR (n=71) | 39.4 |
| Week 16 LDA (n=71) | 49.3 |
| Week 24 CR (n=69) | 47.8 |
| Week 24 LDA (n=69) | 71.0 |
66 and 68 joints were assessed by the physician for tenderness or swelling respectively. The joints were counted as tender/not tender (tender=1; not tender=0) and swollen/not swollen (swollen=1; not swollen=0) and scored. The scores ranged from 0 to 66 for TJC and 0 to 68 for SJC. A negative change from baseline represents an improvement.
| Joints | Tocilizumab Plus MTX |
|---|---|
| Baseline SJC (n=71) | 19.48 ± 10.97 |
| Week 8 SJC (n=71) | 6.72 ± 5.76 |
| Change in SJC from Baseline to Week 8 (n=71) | -12.76 ± 10.93 |
| Week 16 SJC (n=71) | 3.73 ± 4.88 |
| Change in SJC from Baseline to Week 16 (n=71) | -15.75 ± 9.59 |
| Week 24 SJC (n=69) | 2.43 ± 4.12 |
| Change in SJC from Baseline to Week 24 (n=69) | -16.83 ± 9.51 |
| Baseline TJC (n=71) | 24.62 ± 11.84 |
| Week 8 TJC (n=71) | 10.59 ± 8.38 |
| Change in TJC from Baseline to Week 8 (n=71) | -14.03 ± 12.21 |
| Week 16 TJC (n=71) | 7.12 ± 7.25 |
| Change in TJC from Baseline to Week 16 (n=71) | -17.49 ± 11.02 |
| Week 24 TJC (n=69) | 5.03 ± 5.97 |
| Change in TJC from Baseline to Week 24 (n=69) | -19.48 ± 10.27 |
Physician's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.
| mm | Tocilizumab Plus MTX |
|---|---|
| Baseline (n=71) | 67.44 ± 17.72 |
| Week 8 (n=71) | 35.99 ± 20.53 |
| Change from Baseline to Week 8 (n=71) | -31.45 ± 17.76 |
| Week 16 (n=71) | 26.48 ± 20.48 |
| Change from Baseline to Week 16 (n=71) | -40.97 ± 20.7 |
| Week 24 (n=69) | 19.28 ± 17.48 |
| Change from Baseline to Week 24 (n=69) | -48.09 ± 19.69 |
Participant's global assessment of disease activity was performed using a 100 mm VAS ranging from no arthritis activity (0) to maximal arthritis activity (100). The distance in mm from the left edge of the scale was measured. Higher scores indicated higher disease activity. A negative change from baseline represents an improvement.
| mm | Tocilizumab Plus MTX |
|---|---|
| Baseline (n=71) | 70 ± 16.84 |
| Week 8 (n=71) | 42.87 ± 20.67 |
| Change from Baseline to Week 8 (n=71) | -27.13 ± 21.60 |
| Week 16 (n=71) | 33.20 ± 21.16 |
| Change from Baseline to Week 16 (n=71) | -36.80 ± 22.43 |
| Week 24 (n=69) | 24.56 ± 20.15 |
| Change from Baseline to Week 24 (n=69) | -45.30 ± 22.74 |
Participant's global assessment of pain was performed using a 100 mm VAS ranging from no pain (0) at the left edge to unbearable pain (100) at the right edge. The distance in mm from the left edge of the scale was measured. A negative change from baseline represents an improvement.
| mm | Tocilizumab Plus MTX |
|---|---|
| Baseline (n=71) | 69.73 ± 17.60 |
| Week 8 (n=71) | 42.34 ± 19.25 |
| Change from Baseline to Week 8 (n=71) | -27.39 ± 19.44 |
| Week 16 (n=71) | 33.94 ± 21.05 |
| Change from Baseline to Week 16 (n=71) | -35.79 ± 21.52 |
| Week 24 (n=69) | 25.54 ± 21.37 |
| Change from Baseline to Week 24 (n=69) | -44.04 ± 25.11 |
CRP is a marker of acute phase inflammation and is measured in mg/L. A negative change from baseline represents an improvement.
| mg/L | Tocilizumab Plus MTX |
|---|---|
| Baseline (n=62) | 11.98 ± 15.04 |
| Week 8 (n=65) | 5.11 ± 14.12 |
| Change from Baseline to Week 8 (n=61) | -6.68 ± 17.88 |
| Week 16 (n=67) | 3.84 ± 11.91 |
| Change from Baseline to Week 16 (n=60) | -8.0 ± 18.39 |
| Week 24 (n=68) | 5.53 ± 14.07 |
| Change from Baseline to Week 24 (n=60) | -5.97 ± 21.12 |
ESR is a marker of inflammation and is measured in millimeters per hour (mm/hour). A negative change from baseline represents an improvement.
| mm/hour | Tocilizumab Plus MTX |
|---|---|
| Baseline (n=71) | 36.13 ± 24.82 |
| Week 8 (n=71) | 9.04 ± 8.83 |
| Change from Baseline to Week 8 (n=71 | -27.09 ± 22.98 |
| Week 16 (n=71) | 8.71 ± 6.39 |
| Change from Baseline to Week 16 (n=71) | -27.42 ± 23.07 |
| Week 24 (n=69) | 10.3 ± 12.81 |
| Change from Baseline to Week 24 (n=69) | -25.72 ± 27.54 |
AEs, SAEs and AESI were recorded from the Screening Visit until the final visit at Week 24.
| percentage of participants | Tocilizumab Plus MTX |
|---|---|
| AEs | 14.1 |
| SAE | 2.8 |
| AESI | 4.2 |
Collected over Adverse events were recorded from the date of screening until the final visit at Week 24. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab Plus MTX | — | 2/71 (2.8%) | 7/71 (9.9%) |
| Event | Tocilizumab Plus MTX |
|---|---|
| Neoplasm - SkinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/71 |
| Exacerbation of RAImmune system disorders | 1/71 |
| Event | Tocilizumab Plus MTX |
|---|---|
| LeukocytopeniaBlood and lymphatic system disorders | 3/71 |
| Elevated ASTHepatobiliary disorders | 2/71 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/71 |
Intent-to-Treat (ITT) Population: all participants enrolled in the study who completed the baseline visit and received at least 1 dose of study medication.
| Age, Continuous(years) | Tocilizumab Plus MTX |
|---|---|
| Mean | 49.76 ± 12.37 |
| Sex: Female, Male(Participants) | Tocilizumab Plus MTX |
|---|---|
| Female | 61 |
| Male | 10 |
The record gives a start of Feb 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methotrexate · Tocilizumab